Onco Actu du 30 mai 2016

	2.4 Etiologie - Portables, ondes e-m
Health experts question federal study linking cellphones to brain tumors [LA Times] Several raised questions about subjecting rats to radiation for nine hours a day every day from before birth until “old age,” as Dr. Diana C. Haines, a pathologist at the National Cancer Institute, put it in her review. That amount of radiation may not be analogous to “actual human exposure,” she wrote.
ACS Responds to New Study Linking Cell Phone Radiation to Cancer [ACS] The animal studies were performed at very high signal strengths, near but below levels that would cause animal tissue to heat up. Additional research will be needed to translate effects at these high doses to what might be expected at the much lower doses received by typical or even high-end cell phone users.
Questions abound after study links tumors to cellphone radiation [Science] It’s not clear why cancer rates rose in male but not female rats, for instance, or why rats exposed to cellphone radiation lived, on average, longer than radiation-free rats.
What you need to know about the new study on cellphones and cancer [STAT] The study, conducted by the US National Toxicology Program, found a relatively small increase in two types of cancer in rats that were exposed to the kind of radiofrequency radiation that comes from cellphones.
No, a rat study with marginal results does not prove that cell phones cause cancer, no matter what Mother Jones and Consumer Reports say [Science-Based Medicine] From the standpoint of basic science, specifically basic physics and biology, the likelihood that radio waves can cause cancer is incredibly unlikely, or, as I like to put it, not quite homeopathy-level implausible but damned implausible nonetheless.
Yesterday's Cell-Phone Cancer Scare Scares Me A Little About The Future Of Journalism [Forbes] This paper was different. It was published on something called bioRxv, a server for scientific papers run by Cold Spring Harbor Laboratory. It’s modeled on similar servers used by economists and physicists to share papers quickly, without the cumbersome process of going through peer review at medical journals.
A Scary New Study Links Cell Phones And Cancer. Don't Stress. At All. [Forbes] Donald Berry, chairman of the Department of Biostatistics and Applied Mathematics at the University of Texas M. D. Anderson Cancer Center, says that the authors misused statistics, and that no result in the paper should be considered statistically significant.
Cell phone radiation increases cancers in rats; should we worry? [CNN.com] The current report is the first of two installments of the National Institute of Environmental Health Sciences study. The second report, which should be released in the fall of 2017, will include data from mice as well as rats and will look at rates of cancers in other organs and tissue types.
No, Your Cell Phone Probably Isn’t Giving You Cancer [BuzzFeed] The curious finding that male rats in the control group unexposed to cell phone signals died sooner, and that past studies haven’t seen such an effect, “leaves me even more skeptical of the authors’ claims,” Lauer wrote.
Seriously, stop with the irresponsible reporting on cellphones and cancer [Vox] This is how scientists usually think about any important new study. They take the results seriously, they point to questions that demand further investigation, but they remain skeptical that this is the last word. The press should strive to follow suit.
Study Linking Tumors in Rats to Cellphones Raises a Host of Questions [NY Times] The incidence of brain cancer in the United States has remained steady since 1992, despite the stark increase in cellphone use.
Will Your Cellphone Give You Cancer? [NY Times] Recent research has been interpreted as suggesting that cellphones cause cancer. But Gina Kolata explains that the overwhelming evidence suggests that there is no link between the devices and the disease.
	3.1 Tabac
Revealed: cancer scientists' pensions invested in tobacco [The Guardian] Pension fund for academics funded by Cancer Research UK invested £211m in British American Tobacco last year.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA approves new diagnostic imaging agent to detect recurrent prostate cancer [FDA] Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.
	4.12 Biopsies liquides
Oncimmune's cancer test diagnoses '80pc of tumours' early, saving lives [The Telegraph] The Oncimmune tests, which look for cancer antibodies that appear very early on in the blood, could save millions of lives. So far, the company has sold 145,000 lung cancer tests in the US, and hundreds to private hospitals in the UK since launch in 2012.
	5.2 Pharma
Takeda Provides Update on EU Marketing Authorization Application for NINLARO® (ixazomib) in Relapsed/Refractory Multiple Myeloma [Takeda] “We are disappointed by the CHMP’s opinion. With the support of European key medical experts, we will continue our efforts working closely with the CHMP to make NINLARO – the first oral proteasome inhibitor – available for patients in Europe,” said Christophe Bianchi, M.D., President, Takeda Oncology.
	5.3 Traitements - FDA, EMA,...
Improving safety of first-in-human clinical trials [FDA] EMA starts EU-wide reflection on necessary changes to best practices.
After French tragedy, European authorities to review guidelines for clinical trials [STAT] In the wake of a clinical trial in France that recently left one person dead and five others hospitalized, the European Medicines Agency has begun a review of its guidelines for so-called first-in-human studies.
	5.3.4 Traitements - AMM (FDA, EMA)
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma [Takeda] Positive opinion reinforces the role of ADCETRIS in earlier line of treatment in Hodgkin lymphoma.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016 [EMA] The CHMP adopted a negative opinion for Ninlaro (ixazomib). Ninlaro was expected to be used for treating multiple myeloma in adults who had received at least one prior treatment.
	6. Lutte contre les cancers
May 31 set for NCI-MATCH precision medicine trial to resume gene testing of patients [EurekAlert!] Changes have been made to this ground-breaking precision medicine cancer clinical trial, to ensure that more patients will be matched to drugs or drug combinations that target the genetic abnormalities found in their cancer.
	6.11 Patients
Facing my fear: telling a cancer patient he was going to die [The Guardian] Even our team’s most pessimistic moments prior to the biopsy didn’t envisage a disease so aggressive. And now it was my job to tell a 40-year-old man that he probably would die in less than six months. His diagnosis made my own sense of mortality more palpable.
	6.4 Médico-éco
How Wellcome and Gates charities profit from helping biotech [Reuters] The new cancer test called Axumin, which got a green light from the U.S. Food and Drug Administration on Friday, was developed by start-up firm Blue Earth Diagnostics, which is owned by Syncona, Wellcome's biotech investment arm.
	6.5 Médecines alternatives
Yet another woman with breast cancer lured into quackery by Ty Bollinger and “holistic” medicine advocates [Respectful Insolence] Their message seduces patients with curable disease into rejecting the very treatments that can cure them, but, even worse than that, they create “woo multipliers” like Ms. DiNallo who, with every good intention in the world, turn around and do the same thing as Bollinger: Seduce cancer patients into abandoning their best shot at survival in favor of unscientific and pseudoscientific medicine.
	6.6 Publications
All European scientific articles to be freely accessible by 2020 [EU2016.nl] All scientific articles in Europe must be freely accessible as of 2020. EU member states want to achieve optimal reuse of research data. They are also looking into a European visa for foreign start-up founders.
	6.7 DMP, Big Data & applis
How Can Bioinformatics Help Advance Precision Cancer Care? [Dana-Farber Cancer Institute] The cBio Portal software digests the data and presents it in diverse visual formats that help investigators detect patterns of abnormalities across groups of patients and cancer types.
How Can Bioinformatics Help Advance Precision Cancer Care? [Dana-Farber Cancer Institute] The cBio Portal software digests the data and presents it in diverse visual formats that help investigators detect patterns of abnormalities across groups of patients and cancer types.
	6.8 Communication
Five Tips For Consulting Dr. Google on Cancer Treatment and Diagnosis [Memorial Sloan Kettering Cancer Center] After a cancer diagnosis, there are many decisions to be made, from choosing a care team to settling on a treatment. At some point between the consultations and tests, people with cancer are likely to give in to the urge to consult Dr. Google and search for information about their illness online.